Beyond retention and satisfaction, All In Solutions’ 2026 outcomes report also evaluated mental health using two standard, evidence-based tools: the Patient Health Questionnaire-9 (PHQ-9) for depression and the Generalized Anxiety Disorder-7 (GAD-7) for anxiety, both widely used across behavioral health settings to track symptom change.12, 13
Results showed substantial, clinically significant improvements in both depression and anxiety from intake to discharge—evidence that All In Solutions’ integrated approach to co-occurring mental health and substance use disorders is producing tangible benefits.
Among inpatient-only clients (detox or residential at AIS Wellness Center in Florida and AIS Detox in California), average PHQ-9 scores fell by about 4 points, a ~27% reduction in depressive symptom severity, while GAD-7 scores declined by about 27% as well. These changes reflect a shift from moderate symptoms at admission to minimal symptoms at discharge, indicating meaningful emotional relief even over a short inpatient stay.
Clients in outpatient-only programs (PHP/IOP) at AIS Counseling Centers in Florida, New Jersey, and California started with lower baseline scores (about 6–8 on both scales), yet still cut their PHQ-9 and GAD-7 scores roughly in half by discharge. At All In Solutions Counseling Center – New Jersey, for example, PHQ-9 scores dropped from 8.39 to 2.91 and GAD-7 from 8.07 to 2.95. Across all three outpatient sites, discharge averages were in the 2–4 range—levels classified by NICE as “minimal” symptoms.14
The most striking gains occurred among clients who completed the full continuum of care, transitioning from inpatient detox/residential to outpatient (PHP/IOP). These individuals entered with moderate-to-severe depression and anxiety but finished with scores consistent with remission for most participants. In Florida, PHQ-9 scores decreased from 13.05 to 3.55; in California, from 15.75 to 3.72—a ~75–76% reduction in depression severity. Anxiety improved similarly, with GAD-7 scores falling by about 72% (from 12.5 at intake to ~3.5 at discharge). In practical terms, clients began treatment with clinically significant symptoms and were typically discharged in the “minimal” or “subclinical” range (scores <5), aligning with clinical definitions of symptom remission.15